Skip to Main Content

Paper Details

Nomograms to predict outcomes after <sup>177</sup>Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.
Lancet Oncol
110
2021
177Lu, Lutetium-177, PSA, PSMA, Prostate Cancer, [68Ga]Ga, [68Ga]Ga-, [68Ga]Ga-PSMA-11, haemoglobin, mCRPC, men, metastatic castration-resistant prostate cancer, patient, patients, prostate cancer, prostate-specific antigen, prostate-specific membrane antigen, tumour
Author NameAffiliation
Andrei GafitaDavid Geffen School of Medicine, University of California Los Angeles
Jeremie CalaisDavid Geffen School of Medicine, University of California Los Angeles
Tristan GroganDavid Geffen School of Medicine, University of California Los Angeles
Tristan GroganDavid Geffen School of Medicine, University of California Los Angeles
Matthew B Rettiguniversity of california los angeles Medical Center
David ElashoffDavid Geffen School of Medicine, University of California Los Angeles
David ElashoffDavid Geffen School of Medicine, University of California Los Angeles
Johannes CzerninDavid Geffen School of Medicine, University of California Los Angeles
  • 1 - 8

Datasets

Release 1.2